· Published by Health Canada · Official notice
This is duplicated text of a letter from CSL Behring Canada, Inc.
Contact the company for a copy of any references, attachments or enclosures.
May 29, 2012
Dear: Hospital Chief of Medical Staff
Please distribute to relevant departments (Blood Banks; Departments of Transfusion Medicine, Immunology, Hematology, Infectious Diseases, Internal Medicine, and other professional staff/departments involved with IVIGs and post this Notice in your institution).
Subject: Association of hemolysis following the administration of Privigen®, Immune Globulin Intravenous (Human) and related labeling update
CSL Behring Canada, Inc. (CSLB), in collaboration with Health Canada would like to inform you of a recent labeling update regarding the risk of hemolysis following Privigen® administration. Since January 8, 2009, when first marketed in Canada, at least 70 Canadian cases of suspected hemolytic reactions have been reported. Hemolysis reporting rates (i.e., cases per patient-year) among patients receiving Privigen have been stable since the original product launch. Hemolysis is a known class effect associated with the use of intravenous immune globulins. Based on post-marketing safety data gathered by CSLB, the Privigen® Product Monograph has been updated. Hemolysis risk factors are identified below.
Privigen®, Immune Globulin Intravenous (Human), is indicated for the treatment of patients with primary immune deficiency (PID) and secondary immune deficiency (SID) and the treatment of patients with immune thrombocytopenic purpura (ITP) to rapidly raise platelet counts to prevent bleeding.
Delayed hemolytic anemia can develop subsequent to Privigen® therapy due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, has been reported.Footnote 2
Increased vigilance is recommended for non-O blood group patients receiving high doses for non-PID/SID indications. Hemolysis has rarely been reported in patients given replacement therapy for PID/SID.
Immune Globulin Intravenous (Human) or IGIV recipients should be closely monitored for clinical signs and symptoms of hemolysis. If signs and/or symptoms of hemolysis are present after IGIV infusion, appropriate confirmatory laboratory testing should be performed.If transfusion is indicated for patients who develop hemolytic anemia after receiving IGIV, cross-matching should be performed.
The current Product Monograph for Privigen®, dated February 27, 2012, reflects the above information. Contact CSLB Canada at 1-613-783-1892 if you have any questions about this information or the safe and effective use of Privigen.
Managing marketed health product-related adverse reactions depends on health care professionals and consumers reporting them. Reporting rates determined on the basis of spontaneously reported post-market adverse reactions are generally presumed to underestimate the risks associated with health product treatments. Any case of hemolysis or other serious or unexpected adverse reactions in patients receiving Privigen® should be reported to CSL Behring or to Health Canada.
Please report any suspected adverse event your patient encounter with a CSL Behring Product to CSL Behring U.S. Clinical Safety and Pharmacovigilance: 1-866-915-6958. Please provide the lot number(s) of products associated with reported adverse events whenever possible.
CSL Behring Canada, Inc.
55 Metcalfe Street, Suite 1460
Ottawa, Ontario
K1P 6L5
To correct your mailing address or fax number, contact CSL Behring Canada, Inc.
To report suspected adverse reactions to these or other health products, please contact Health Canada's Canada Vigilance Program toll-free at 1-866-234-2345, or visit the MedEffect™ Canada Web site for information on how to report.
The Reporting Forms, postage paid labels, and Guidelines can be found on the MedEffect™ Canada Web site in the Adverse Reaction Reporting section. The Reporting Form is also in the Canadian Compendium of Pharmaceuticals and Specialties.
For other health product inquiries related to this communication, please contact Health Canada at:
Marketed Health Products Directorate
E-mail: mhpd_dpsc.public@hc-sc.gc.ca
Telephone: 613-954-6522
Fax: 613-952-7738
Sincerely,
original signed by
Susanne Picard, B. Pharm., M. Sc.
Director, Regulatory Affairs Canada
CSL Behring Canada, Inc.
Daw Z, Padmore R, Neurath D, et al. Hemolytic transfusion reactions after administration of intravenous immune (gamma) globulin: A case series analysis. Transfusion 2008; 48:1598-1601.
Kessary-Shoham H, Levy Y, Shoenfeld Y, Lorber M, Gershon H. In vivo administration of intravenous immunoglobulin (IVIg) can lead to enhanced erythrocyte sequestration. J Autoimmun 1999; 13:129-135.